Assessing the economic value of anticancer therapies.
Neymark
N
N
EORTC Health Economics Unit, Brussels, Belgium.
D000900:Anti-Bacterial Agents / Q000191:economics; D000932:Antiemetics / Q000191:economics; D001943:Breast Neoplasms / Q000191:economics / Q000628:therapy; D003110:Colonic Neoplasms / Q000191:economics / Q000628:therapy; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D019049:Developed Countries; D005260:Female; D017048:Health Care Costs; D005102:Health Expenditures; D006397:Hematinics / Q000191:economics; D019337:Hematologic Neoplasms / Q000191:economics / Q000628:therapy; D006801:Humans; D008175:Lung Neoplasms / Q000191:economics / Q000628:therapy; D008297:Male; D009369:Neoplasms / Q000191:economics* / Q000453:epidemiology / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000191:economics / Q000628:therapy; D010166:Palliative Care / Q000191:economics; D011471:Prostatic Neoplasms / Q000191:economics / Q000628:therapy; D012004:Rectal Neoplasms / Q000191:economics / Q000628:therapy; D016378:Tissue Transplantation / Q000191:economics; D014565:Urogenital Neoplasms / Q000191:economics / Q000628:therapy
D000900:Anti-Bacterial Agents; D000932:Antiemetics; D006397:Hematinics